News und Analysen
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.
On May 21, 2025
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product
EQS-News: Eckert & Ziegler Wins “Best Managed Companies Award” for the Second Time
Siegfried expands production capacity for ophthalmic drugs in El Masnou
QuidelOrtho to Participate in Upcoming Investor Conferences
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine
Humana Foundation Donates $50,000 to Support Long-Term Recovery in Tornado-Impacted Kentucky Communities
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), announced today a $50,000 contribution to advance sustained recovery efforts in Kentucky communities devastated by the most
Savara Announces Participation in Jefferies Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and
STAAR Surgical Announces Participation in Upcoming Investor Conferences
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week
Agilent Announces Cash Dividend of 24.8 Cents per Share
Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of
Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pascal Soriot and Judy Gawlik Brown Named to Agilent Board of Directors
Agilent Technologies Inc. (NYSE: A) today announced that Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, have been elected to its Board of Directors
Uni-Bio Science Group Receives NMPA Approval for 金因康® (Diquafosol Sodium Eye Drops), Advancing Dry Eye Syndrome Treatment in China
EQS-News: M1 Kliniken AG: Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership
Humana Foundation CEO, Tiffany Benjamin, Named to the Inaugural TIME100 Philanthropy List
The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, is proud to announce that Tiffany Benjamin, the foundation’s CEO, has been named to the inaugural TIME100
Agilent Announces My Green Lab Ecolabel 2.0 for the New Infinity III LC Series
Agilent Technologies Inc. (NYSE: A) today announced that the Infinity III LC Series — the company’s latest liquid chromatography (LC) instruments — are the first Agilent instruments to receive the
EQS-News: BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the
ICON releases its ICON Cares 2024 Report
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company’s 2025 annual stockholders’ meeting.
Stockholders ratified the continuation of
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS
STAAR Surgical Announces $30 Million Share Repurchase Authorization
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of
Agilent to Participate in Jefferies Global Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at the Jefferies Global Healthcare Conference at